NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers

August 28, 2018 |

2 min read

Assists device manufacturers to simplify the process of identifying the correct biological endpoint assessments for intended global regulatory submission pathways

TOLEDO, Ohio--(BUSINESS WIRE)-- NAMSA^®, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory testing, clinical research and regulatory consulting services is pleased to announce the launch of its new online development application, the NAMSA Biocompatibility Strategy Navigator.

This first-of-a-kind web-based resource assists device manufacturers to simplify the process of identifying the correct biological endpoint assessments for intended global regulatory submission pathways. Utilizing the most up-to-date regulatory requirements to determine strategic results, the Biocompatibility Strategy Navigator provides instant recommendations to assist manufacturers to cost-effectively streamline development initiatives.

“We are extremely pleased to offer the industry’s first online solution designed to provide medical device organizations with unprecedented, customized access to the biological tests required for regulatory approval. This novel application is the only resource available in the marketplace with no-cost, open access that delivers strategic recommendations in four simple steps,” commented Jean-Pierre Boutrand, Vice President of Global Laboratory Services, NAMSA.

The medical device industry’s definitive resource for laboratory testing for over 50 years, NAMSA offers clients world-class programs that fast-track development efforts and deliver cost-efficient development solutions. To date, NAMSA has helped thousands of clients ensure that their devices enter the international marketplace in the most safe and efficacious manner possible. NAMSA is proud to continue its reputation as the premier industry partner for toxicology, microbiology, chemistry and biocompatibility testing services.

Boutrand concluded, “We are confident that this new application will serve as a valuable resource for global manufacturers as we work together to bring life-saving medical technologies to the market in the most efficient manner possible.”

To access NAMSA’s Biocompatibility Strategy Navigator, please visit: namsa.com/biocompatibility-strategy-navigator. Clients may also meet with NAMSA’s medical device development experts on-site at the following upcoming events: https://www.namsa.com/resources/events/.

About NAMSA

NAMSA is a Medical Research Organization (MRO), accelerating medical device product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA’s MRO® Approach plays an important role in translational research, applying a unique combination of disciplines – consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality – to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements anywhere in the world.

NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs over 1,000 highly-experienced laboratory, clinical and consulting Associates.